|
|
||||||||
CLINICAL STUDY |
L Alves, Department of Hygiene and Epidemiology, University of Porto Medical School; Institute of Public Health - University of Porto (ISPUP), Porto, Portugal
A Azevedo, Department of Hygiene and Epidemiology, University of Porto Medical School; Institute of Public Health - University of Porto (ISPUP), Porto, Portugal
Correspondence: Luis Alves, Email: luisaaalves{at}gmail.com
Abstract
Background: We aimed to estimate (1) the prevalence of hypercholesterolemia, (2) the proportion of individuals eligible for treatment with lipid-lowering drugs, and (3) therapeutic success, according to the European guidelines on cardiovascular disease prevention in clinical practice.
Design: Population-based cross-sectional study.
Methods: We surveyed a representative sample of the population of Porto aged 40-65 years. Trained interviewers collected data from 1215 subjects (789 women) on demographic variables, medical history and medication using structured questionnaires. A fasting venous blood sample was withdrawn. Subjects were considered low-risk or high-risk as indicated in the European guidelines. Hypercholesterolemia was defined as total cholesterol (TC)
5mmol/L or LDL-cholesterol (LDL-C)
3mmol/L in low-risk subjects, TC
4.5mmol/L or LDL-C
2.5mmol/L in high-risk subjects or being medicated with lipid lowering drugs. Eligibility for treatment was defined as being high-risk and having TC
4.5mmol/L, LDL-C
2.5mmol/L or being on treatment. We defined therapeutic success as having TC <4.5mmol/L and LDL-C <2.5mmol/L among medicated subjects.
Results: Overall, 84.9% (95% confidence interval (95% CI): 82.7-86.8) of subjects had hypercholesterolemia and 9.1% (95% CI: 7.5-10.8) were medicated with lipid-lowering drugs. Men were more likely to be eligible for treatment (42.4%) than women (22.4%) (OR=2.69, 95%CI 2.07-3.52). Therapeutic success was less frequent in men (46.8%) than in women (66.7%), (OR=0.39, 95% CI 0.17-0.87).
Conclusion: Strict interpretation of the European guidelines would label 85% of the general population in this age group as hypercholesterolemic and a third eligible for drug treatment. Questions arise regarding medicalization, resource allocation and sustainability within the healthcare system.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |